FDA Approves Inavolisib Combo for PIK3CA-Mutated, HR+ Breast Cancer.

IF 3.5 4区医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Current medicinal chemistry Pub Date : 2025-01-01 DOI:10.2174/0109298673365863250101070254

Jinwei Zhang

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

FDA批准Inavolisib组合治疗pik3ca突变的HR+乳腺癌

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current medicinal chemistry 医学-生化与分子生物学

CiteScore

8.60

自引率

2.40%

发文量

468

审稿时长

3 months

期刊介绍： Aims & Scope Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews and guest edited thematic issues written by leaders in the field covering a range of the current topics in medicinal chemistry. The journal also publishes reviews on recent patents. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.

期刊最新文献

Reduced Expression of LINC01515 Suppresses Proliferation and Invasion of Lung Adenocarcinoma Cells via Modulation of the miR-33a-5p/HMGA2 Signaling Axis. In Vitro, In Vivo and Ex Vivo Irradiation Research of Low-frequency Ultrasound Combined with Chemotherapy for Ovarian Carcinoma Cells. Broccoli and Other Botanicals in the Prevention and Treatment of Premenstrual Syndrome. Unveiling the Small Molecules Binding Site of CD36 Cell Surface Receptor Through Docking and Molecular Dynamics Simulations. Herbal Medicines and Drugs Interactions: Cytochrome P450 Responsibility.